(Press-News.org) Over the period 2018 – 2023, EULAR, the leading organisation in RMDs, has grown substantially and has been professionalised in every aspect. For example, EULAR has increased its impact on RMDs through the development of new services provided by the EULAR Research Centre (ERC). Despite the disruption of routine procedures brought about by the pandemic, EULAR overcame the substantial associated challenges, providing continued access to education and networking for the RMD community. “We have made tremendous progress by setting up two virtual congresses and one fully hybrid congress, and we have taken great steps in quality of care, advocacy, and governance”, says the President Prof Annamaria Iagnocco. “The new strategy will build on and extend this excellent fundament.”
The new strategy for 2024 – 2028 is driven by a vision of a world where all RMDs are recognised, diagnosed, and ultimately prevented or cured. To realise this vision, EULAR’s mission is to minimise the impact of RMDs on individuals and society. EULAR promotes education, awareness, best clinical care, prevention, and research in the field of RMDs, as well as providing global solutions for the management of RMDs.
“To achieve real impact, we have built a clear strategy which includes actionable and measurable goals”, says Prof Annamaria Iagnocco. “We will pursue four main objectives”:
Leadership, Scientific Guidance, and Innovation: EULAR’s visionary goals require clear leadership: EULAR will increase the visibility and impact of RMDs in politics and policy nationally and internationally. It will take a clear lead in innovation in RMDs. In doing so, EULAR will be the respected and valued voice of RMDs globally.
Professional and Personal Development: EULAR’s ambitions require the necessary expertise in researchers and practitioners delivering care: EULAR will support personal and professional development to improve skills and expertise within and outside of EULAR. It will provide the foundation for personal growth by positioning the necessary frameworks of competencies and providing education. In doing so, early career rheumatologists, health professionals and representatives of people with RMDs will be particularly considered.
Communities: EULAR aims to build strong communities of people concerned with RMDs that join forces to realise their ambitions. The management of communities will be strengthened, and the interactions of individuals both within and around EULAR will be furthered. Interaction with members, partner organisations and other stakeholders will be improved. To achieve this goal, EULAR will broaden its membership base by including individual members. Supporting all kinds of members will be an important concern.
Viable economic base: EULAR strives to secure its economic foundation well into a future where previous funding sources can no longer be taken for granted. A viable economic base is a precondition for the services that EULAR provides to the RMD community and the wider world.
“Our goals are very ambitious. But among the values, which form an important part of our strategy, are flexibility and dedication”, says Prof Annamaria Iagnocco. “We deeply appreciate and are thankful for our volunteer's dedicated work.” With a committed base of volunteers and a highly professional organisation in its Swiss-based office, EULAR is in an excellent position to realize its ambitions.
About EULAR
EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.
Contact
EULAR Communications, communications@eular.org
Notes to Editors
EULAR Recommendations
EULAR School of Rheumatology
EULAR Press Releases
END
The European Alliance of Associations For Rheumatology, EULAR, announces its strategy for 2024 – 2028
Extending EULAR’s leadership in rheumatic and musculoskeletal diseases and building a sound fundament for delivering expertise to the world.
2023-06-01
ELSE PRESS RELEASES FROM THIS DATE:
EULAR launches ‘RheumaFacts’, a unique and Pan-European data repository of rheumatic and musculoskeletal disease indicators
2023-06-01
The European Alliance of Associations for Rheumatology (EULAR) is proud to announce the launch of RheumaFacts, an innovative and unique resource of facts and figures related to rheumatic and musculoskeletal diseases (RMDs) across Europe. Strategically developed to support EULAR’s mission of reducing the impact of RMDs on individuals and society, RheumaFacts will serve as a powerful tool to provide healthcare professionals, researchers, policymakers, and patients with data-driven insights on the status of rheumatologic care across EULAR’s ...
EULAR launches first European patient-filled survey about the impact of rheumatic and musculoskeletal diseases on individual’s lives
2023-06-01
The European Alliance of Associations for Rheumatology (EULAR) has announced the launch of the EULAR Impact of RMDs Survey, an online questionnaire targeted directly at RMD patients. The data collected through this survey will be an important resource for researchers, healthcare professionals, and patients alike, providing a comprehensive database of patient-reported outcomes on their healthcare situation, and how the illness affects their social and occupational lives. By collecting and analysing data from a large number of patients with RMDs on a recurring basis, the survey will provide valuable insights into the burden of disease and help improve the overall care for people living with ...
Rheumatic and musculoskeletal diseases (RMDs) often accelerate lethal comorbidities
2023-06-01
Rheumatic and musculoskeletal diseases (RMDs) include over 200 diseases that affect over 120 million Europeans of all ages. Aside from the significant direct impact RMDs have on patients, many of them also pose a further significant risk to the population by virtue of accelerating many comorbidities if the RMD is not treated appropriately. The most significant comorbidities of inflammatory RMDs include cardiovascular disease, lung disease, cancers, gastrointestinal disease, and mental health disorders.[1] Many of these comorbidities are prioritised by the EU as key non-communicable ...
Stand Up to Cancer announces $1.5 million commitment from Pancreatic Cancer North America to fund pancreatic cancer vaccine research
2023-06-01
LOS ANGELES – June 1, 2023 – Stand Up To Cancer® (SU2C) and Pancreatic Cancer North America (PCNA) today announced that PCNA will contribute $1.5 million to SU2C in support of critically needed research focused on pancreatic cancer, which has the highest mortality rate of all major cancers.
One of the projects supported by PCNA will include a correlative study that analyzes data from a previous Phase 1 clinical trial conducted by a Research Team funded through the SU2C Convergence program and led by researchers at Memorial ...
Rethink, rewrite, redefine—how biodegradable plastics are reshaping sustainability
2023-06-01
The University of California San Diego’s vision is to be a student-centered, research-focused, service-oriented public university. There are countless examples across campus of the ways these three pillars are upheld, but it is unique to find all three incorporated at once. Now a new book on algae-based biodegradable plastics showcases student research and the monumental potential it has to change consumerism on a global scale.
Statistics on the environmental damage of plastics are stark: in 2018, U.S. landfills received 27 million tons of plastic (U.S. Environmental Protection Agency); ...
ComboMATCH investigators are translating robust pre-clinical evidence for new anti-cancer drug combinations into a series of early-phase clinical trials
2023-06-01
Five leading cancer research organizations in the United States are jointly announcing the start of patient enrollment in Molecular Analysis for Combination Therapy Choice (ComboMATCH), a unique, precision medicine initiative to test new combinations of cancer drugs guided by tumor biology. The Alliance for Clinical Trials in Oncology, Children's Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network plan to conduct many early-phase treatment trials through this platform in collaboration with the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). NCI is part of ...
Parkinson’s disease drug ropinirole safely slowed the progression of ALS for over 6 months in a clinical trial
2023-06-01
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal motor neuron disease that causes people to gradually lose control of their muscles. There is no cure, and current treatments focus on reducing symptoms and providing supportive care. Reporting June 1 in the journal Cell Stem Cell, researchers from Japan show in an early clinical trial that the Parkinson’s disease drug ropinirole is safe to use in ALS patients and delayed disease progression by 27.9 weeks on average.
Some patients were more responsive to ropinirole treatment than others, and the researchers ...
The 'breath' between atoms — a new building block for quantum technology
2023-06-01
University of Washington researchers have discovered they can detect atomic "breathing," or the mechanical vibration between two layers of atoms, by observing the type of light those atoms emitted when stimulated by a laser. The sound of this atomic "breath" could help researchers encode and transmit quantum information.
The researchers also developed a device that could serve as a new type of building block for quantum technologies, which are widely anticipated to have many future applications in fields such as computing, ...
CHOP researchers use “deep sequencing” to identify several previously undescribed genetic variants in vascular anomalies
2023-06-01
Philadelphia, June 1, 2023 – Researchers from Children’s Hospital of Philadelphia (CHOP) recently discovered that extremely thorough “deep sequencing” of the genome in tissue samples and cell-free DNA of patients with potentially life-threatening vascular anomalies captured several genetic variants related to disease that were not captured with conventional genetic sequencing methods. More than 60% of patients saw an improvement in their condition after being placed on targeted therapies related to these newly found genetic variants. The findings were published today in the journal Nature Medicine.
Vascular ...
Quantifying mangroves’ value as a climate solution and economic engine
2023-06-01
A tiny Central American country is charting a path to slowing climate change, while boosting the economy and making communities safer. A new Stanford-led study quantifies the value of Belize’s coastal mangrove forests in terms of how much carbon they can hold, the value they can add to tourism and fisheries, and the protection they can provide against coastal storms and other risks. Importantly, the findings, published June 1 in Nature Ecology and Evolution, have already provided a basis for Belize’s commitment to protect or restore additional mangrove forests totaling an area about the size ...
LAST 30 PRESS RELEASES:
COVID-19 pandemic drove significant rise in patients choosing to leave ERs before medically recommended
Burn grasslands to maintain them: What is good for biodiversity?
Ventilation in hospitals could cause viruses to spread further
New study finds high concentrations of plastics in the placentae of infants born prematurely
New robotic surgical systems revolutionizing patient care
New MSK research a step toward off-the-shelf CAR T cell therapy for cancer
UTEP professor wins prestigious research award from American Psychological Association
New national study finds homicide and suicide is the #1 cause of maternal death in the U.S.
Women’s pelvic tissue tears during childbirth unstudied, until now
Earth scientists study Sikkim flood in India to help others prepare for similar disasters
Leveraging data to improve health equity and care
Why you shouldn’t scratch an itchy rash: New study explains
Linking citation and retraction data aids in responsible research evaluation
Antibody treatment prevents severe bird flu in monkeys
Polar bear energetic model reveals drivers of polar bear population decline
Socioeconomic and political stability bolstered wild tiger recovery in India
Scratching an itch promotes antibacterial inflammation
Drivers, causes and impacts of the 2023 Sikkim flood in India
Most engineered human cells created for studying disease
Polar bear population decline the direct result of extended ‘energy deficit’ due to lack of food
Lifecycle Journal launches: A new vision for scholarly publishing
Ancient DNA analyses bring to life the 11,000-year intertwined genomic history of sheep and humans
Climate change increases risk of successive natural hazards in the Himalayas
From bowling balls to hip joints: Chemists create recyclable alternative to durable plastics
Promoting cacao production without sacrificing biodiversity
New £2 million project to save UK from food shortages
SCAI mourns Frank J. Hildner, MD, FSCAI: A founder and leader
New diagnostic tool will help LIGO hunt gravitational waves
Social entrepreneurs honored for lifesaving innovations
Aspects of marriage counseling may hold the key to depolarizing, unifying the country, study finds
[Press-News.org] The European Alliance of Associations For Rheumatology, EULAR, announces its strategy for 2024 – 2028Extending EULAR’s leadership in rheumatic and musculoskeletal diseases and building a sound fundament for delivering expertise to the world.